Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.

① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?

cls.cnDec 2 21:48 ET

China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.

Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.

Zhitong FinanceDec 2 00:42 ET

National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.

1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?

cls.cnNov 26 21:39 ET

Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.

Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.

Zhitong FinanceNov 26 20:47 ET

Sihuan Pharm (00460.HK) spent 6.964 million Hong Kong dollars to repurchase 10 million shares on November 26th.

Gelonghui, November 26 - Sihuan Pharm (00460.HK) announced that on November 26, it spent 6.964 million HKD to repurchase 10 million shares, with a repurchase price of 0.68-0.71 HKD per share.

Gelonghui FinanceNov 26 05:51 ET

HK Stock Market News | Sihuan Pharm (00460) surged nearly 6% in the final trading session, planning to spin off Xuanzhu Biopharma for listing in Hong Kong. Two subsidiaries have reached an exclusive licensing agreement for weight loss drugs.

Sihuan pharm (00460) rose nearly 6% at the close, as of the time of writing, it rose 4.48%, priced at 0.7 Hong Kong dollars, with a transaction amount of 20.261 million Hong Kong dollars.

Zhitong FinanceNov 26 02:48 ET